European Registry of Next Generation Imaging in Advanced Prostate Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Imaging: Imaging will be done according to local protocols and/or guidelines of EAU

Study summary

The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging.

Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form.

Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.

Eligibility

Primary outcome measure(s)

• Proportion of patients requiring NGI, conventional imaging, or a combination of both imaging tools. — 4 - 6 weeks
  Number of patients who require NGI, conventional imaging, or a combination of both imaging tools with the respect to local protocols
• Proportion of patients with a change of treatment determined by the imaging test result, when multiple imaging tests have been realized — 4-6 weeks
  Number of patients who received multiple imaging tests for whom the result of the particular imaging test has lead to the change in management

Trial sites (24)

Other trials for the same condition